Nearly 20 states are moving to restrict assistance programs that help people afford HIV medications and treatment.

Eighteen states are limiting access to HIV medications through ADAP programs as federal funding has remained largely flat despite rising costs, with others considering similar cuts.

Single-pill treatment proves as effective at suppressing virus as multi-pill therapy, while long-acting preventive injections are increasingly available ...

Citing rising costs and shortfalls in federal support, about 20 states are toughening eligibility requirements for patients ...

The consolidated evidence reveals that there is considerable cross-country price variation, particularly for second-line regimens where prices increase significantly with income level highlighting ...

Post-exposure prophylaxis-in-pocket (PIP) was associated with healthcare savings and improved quality of life outcomes compared to pre-exposure prophylaxis (PrEP), based on data presented at ...

The gutting of HIV drug programs isn't just bad policy; it threatens a repeat of history's deadliest mistake, writes John ...

As the 2026 Conference on Retroviruses and Opportunistic Infections (CROI) wrapped up, leading HIV experts reflected on the ...

LONDON (Reuters) - The International HIV/AIDS Alliance warned on Saturday that the annual cost of tackling the HIV epidemic could balloon to $35 billion by 2030 if governments fail to invest in ...

Long-acting antiviral medications are transforming HIV prevention and care, requiring only minimalistic dosing. But as the use of lenacapavir expands, scientists are probing a critical question: If ...

Three experimental injectable antiretrovirals – a novel capsid inhibitor and two next-generation integrase inhibitors – could ...